J B Chemicals & Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• J B Chemicals & Pharmaceuticals Ltd reported a 0.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.9%.
• Its expenses for the quarter were down by 1.9% QoQ and up 6.1% YoY.
• The net profit increased 2.7% QoQ and increased 19.0% YoY.
• The earnings per share (EPS) of J B Chemicals & Pharmaceuticals Ltd stood at 13.08 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

J B Chemicals & Pharmaceuticals Ltd, a notable entity in the pharmaceutical industry, specializes in the production and marketing of a diverse array of pharmaceutical products. The company is recognized for its expertise in the formulation of high-quality medications, serving a broad spectrum of therapeutic areas. Despite the lack of specific recent developments included in the provided data, J B Chemicals & Pharmaceuticals Ltd continues to uphold its reputation within the industry as a reliable manufacturer and distributor. The company operates with a focus on innovation and quality, contributing to the healthcare sector by delivering effective solutions for various medical needs.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), J B Chemicals & Pharmaceuticals Ltd reported total income amounting to ₹1,100.24 crores. This figure reflects a slight decline of 0.7% compared to the preceding quarter (Q1FY26), where total income was ₹1,108.49 crores. However, on a year-over-year basis, there was a growth of 8.9% from the same quarter in the previous year (Q2FY25), where the total income was ₹1,010.57 crores. This data illustrates a year-over-year increase, despite the quarter-over-quarter decrease in revenue.

Profitability

The company's profit before tax (PBT) for Q2FY26 was ₹279.15 crores, which marks a 2.8% increase from the previous quarter, where the PBT was ₹271.61 crores. On a year-over-year comparison, the PBT showed a significant rise of 18.0% from Q2FY25, where it was ₹236.53 crores. The tax expenses for Q2FY26 stood at ₹71.33 crores, reflecting an increase of 3.0% quarter-over-quarter and 15.1% year-over-year. Consequently, the profit after tax (PAT) for the quarter reached ₹207.82 crores, marking a 2.7% increase from Q1FY26 and a notable 19.0% rise compared to Q2FY25. The Earnings Per Share (EPS) for Q2FY26 was ₹13.08, representing a 2.6% increase from the previous quarter and an 18.9% increase from the same quarter in the previous year.

Operating Metrics

The total expenses for J B Chemicals & Pharmaceuticals Ltd in Q2FY26 were ₹821.09 crores, which shows a reduction of 1.9% from the previous quarter's total expenses of ₹836.88 crores. When compared to the same quarter last year, there was an increase of 6.1% from ₹774.04 crores. The company's ability to manage its expenses effectively is reflected in the numbers, which contributed to the profitability metrics. The decrease in total expenses quarter-over-quarter alongside the increase year-over-year indicates a level of operational efficiency in managing costs while increasing revenue over the annual period.